NTS is developing a pipeline of disease-modifying molecules designed to address the acute and post-injury deficits that can persist for weeks to years following a brain injury.

NTS-104 is the pro-drug of NTS-105, which is a novel neurosteroid demonstrating a unique pharmacologic profile including anti-inflammatory and cytoprotective actions. NTS-104 has shown efficacy in multiple pre-clinical models of acute ischemic stroke and TBI. NTS-105 readily enters the brain and potently modulates key target receptors, protecting cells from inflammation, ischemia, and hypoxia.

Phase 1
Phase 2
Phase 3
NTS-104 NTS-105
Acute Ischemic Stroke (with MT)
Chronic Stroke (with PT)
Acute Mild TBI (with CT+ Scan)
Chronic TBI
Hemorrhagic Stroke
Chronic Subdural Hematoma (CSDH)

A chronic subdural hematoma (CSDH) typically occurs after a head injury and is characterized by a collection of blood on the brain’s surface, under the outer covering of the brain (dura). CSDH is an inflammatory disease and is one of the most common neurosurgical conditions. CSDH represents a major cause of increased cost of health and disability worldwide. CSDH is projected to become the most common neurosurgical disease by 2030 in the United States.1

1. David Balser J Neurosurg 2015 Nov;123(5):1209-15. doi: 10.3171/2014.9.JNS141550. Epub 2015 Mar 20.